John Mascarenhas, MD, on the Phase III PACIFICA Trial of Pacritinib in Myelofibrosis
By Leah Sherwood, John Mascarenhas, MD - Last Updated: April 12, 2023John Mascarenhas, MD, discusses the phase III PACIFICA study on the dual JAK2 and FLT3 inhibitor pacritinib in patients with myelofibrosis. The results were presented at the 2022 American Society of Hematology Annual Meeting.
Advertisement
Post Tags:MPN ASH 22
Advertisement
Related Posts
New data on immune thrombocytopenia were most prominent but Meeting coverage ranged over several forms of the disease.
Andrew Kuykendall, MD, presented on the status of myelofibrosis treatment in the era of 4 approved JAK inhibitors.
The CARTITUDE-4, KarMMa-3, and DREAMM-7 trials are paving the way for immunotherapy in multiple myeloma.
A panel moderated by Neil Love, MD, explored clinical data to assess these treatment approaches for the various types of NHL.
The several considerations involved with these agent classes make discussions with patients of treatment decisions crucial.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.